Shikiar Asset Management Inc. Sells 1,070 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Shikiar Asset Management Inc. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 56.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 838 shares of the biopharmaceutical company's stock after selling 1,070 shares during the period. Shikiar Asset Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $736,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Sunbelt Securities Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $25,000. Fortitude Family Office LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $31,000. Criterion Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $37,000. Finally, Bruce G. Allen Investments LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $40,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. UBS Group raised their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a "buy" rating in a research note on Wednesday. Cantor Fitzgerald restated a "neutral" rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 13th. Bank of America lifted their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an "underperform" rating in a research note on Friday, April 12th. Finally, BMO Capital Markets lifted their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an "outperform" rating in a research note on Monday, February 5th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $976.41.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares of the company's stock, valued at $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the business's stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares of the company's stock, valued at approximately $12,888,716.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the business's stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares of the company's stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 13,729 shares of company stock valued at $13,124,641 over the last ninety days. 8.83% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $2.83 during trading on Friday, reaching $896.82. The company's stock had a trading volume of 507,466 shares, compared to its average volume of 412,356. The stock has a 50-day moving average price of $953.01 and a two-hundred day moving average price of $892.21. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The stock has a market capitalization of $98.43 billion, a P/E ratio of 25.81, a price-to-earnings-growth ratio of 2.59 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion during the quarter, compared to analysts' expectations of $3.29 billion. During the same period in the previous year, the business posted $10.96 earnings per share. The firm's revenue for the quarter was up .6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.